The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors

1The incidence of invasive fungal infections has increased during the past three decades, arising more and more concern. For example, statistics show that such incidence ranges from 30 to 40% throughout critical ill patients. Prognosis of invasive fungal infections is serious. Specifically, the mortality rate of systemic C. albicans infection is up to 40%. Risk factors, such as gastrointestinal surgery, widespread use of broad-spectrum antibiotics and popularization of central venous catheters (CVCs) mainly contribute to the invasive C. albicans infection. At the same time, non-Candida fungal infections should not be neglected, as cryptococcosis is the third prevalent disease in HIV-positive patients, and the mortality of invasive aspergillosis at 30 days in adult ICU patients is estimated to be 33.1%.

2Represented by azole resistance, the continuous emergence of drug-resistant fungal strains has become a serious challenge for public health. CYP51 (ERG11) proteins is the target of azoles, which mediates membrane permeability and fluidity by demethylating the 14-α position of lanosterol to form ergosterol. In attribution to the constant emergence of azole-resistant isolates, a critical understanding of the resistance mechanisms of CYP51 is required for the discovery of novel CYP51 inhibitors.

3Sterol synthesis is a very ancient pathway. After the appearance of molecular oxygen in the atmosphere, squalene-2,3-epoxide is formed and then cyclized to steroid precursors, such as lanosterol. Under the oxidative removal of methyl groups by CYP51, these precursors were transformed into ergosterol, which is critical in membrane permeability and fluidity in the fungal kingdom.

4Cytochrome P450s (P450s, CYP) are an abundant hemease superfamily. As the first group of enzymes ranked as “superfamily,” cytochrome P450s play an important role in the primary as well as secondary metabolic pathways. Until August 2013, this superfamily contained 10 classes, 267 families and over 21,000 members. These members are important for catalyzing the oxidative process of various organic substrates, and play a critical role during heterogeneous metabolism and steroid conversion in biological kingdoms.

5CYP51 proteins belong to the CYP superfamily and is the most conserved protein in it. Unlike other CYP enzymes, CYP51 has a strong specificity. It only catalyzes the demethylation of a very narrow range of substrates, including lanoserol, obtusifoliol, 24,25-dihydrolanosterol, 24-methylenedihydrolanosterol and 4 β-desmethyllanosterol. The CYP51-involved catalytic reaction consists of three steps, each of which requires one molecule of oxygen and two molecules of NADPH-sourced reduction equivalent. The first two steps are typical cytochrome P450 monooxygenation processes, during which the 14α methyl is converted to methyl alcohol and further converted to methyl aldehyde. And in the last step, the aldehyde group is transformed into formic acid and detached, accompanied with the synthesis of the Δ-14, 15 double bond.

6The 14α-demethylase is the only invariant P450 present in all sterol biosynthetic pathways, suggesting that all sterol 14α-demethylases share a common prokaryotic ancestor. CYP51s are widely distributed in the fungal kingdom. However, in different species of fungi, there are still differences in the types and subtypes, as shown in the phylogenetic tree (Figure 1). Only one CYP51 gene exists in the pathogenic fungi C. albicans, which belongs to the Ascomycota Saccharomycotina. In contrast, 2 or 3 CYP51 genes are commonly contained in the Ascomycota Pezizomycotina genomes, including CYP51A and CYP51B. CYP51C is exclusive in Fusarium spp.. Some Aspergillus Spp. such as A. fumigatus carries only one CYP51A and one CYP51B protein, while other Aspergillus species such as A. flavus and A. terreus carry a third paralogous gene, which is a copy of CYP51A or CYP51B. Studies on Aspergillus fumigatus have shown that CYP51B is constitutively expressed, while CYP51A is expressed in an inducible manner. Neither CYP51A nor CYP51B is essential for in vitro growth and virulence, and only the simultaneous inactivation of both genes is lethal.

7A recent study also showed that CYP51 might have a number of indirect functions. In C. albicans, the deletion of CYP51 (ERG11) reduces mycelial elongation and invasive growth, and causes defects of reactive oxygen elimination, resulting in reduced virulence in vivo. It is worth paying special attention that ERG11-deficient fungi are more susceptible to phagocytosis by macrophages, which indicates that CYP51 may be critical for the immune escape process in fungi.

8Present in all animals, plants, fungi, in some protozoa and bacteria, the CYP51 protein located in the inner face of the endoplasmic reticulum is a membrane monospanning enzyme. And its N-terminus includes an amphipathic helix, which links the catalytic subunit to the lipid bilayer. Besides crystallographic structures of CYP51 proteins from some protozoa and bacteria, and the ligand-free CYP51 proteins from Homo sapiens (3JUV) and complexed with ketoconazole (3LD6) deposited in Protein Data Bank (PDB). X-ray structures of CYP51 proteins of some fungi have already been described in literature, including CYP51 proteins from Saccharomyces cerevisiae complexed with the substrate lanosterol (4LXJ) and complexed with itraconazole (5EQB), voriconazole (5HS1) and fluconazole (4WMZ), from C. albicans complexed with posaconazole (5FSA) and the tetrazole-based antifungal drug candidate VT1161 (VT1) (5TZ1), and CYP51B structure in complex with the VNI derivative (6CR2) and a tetrazole-based inhibitor VT-1598 (5FRB) from A. fumigates.

9Together with information from the analysis of multiple-sequence alignment of CYP51 proteins from human and fungi including S. cerevisiae, C. albicans, C. glabrata, C. tropicalis, C. krusei, C. dubliniensis, C. parapsilosis, A. fumigatus and Cryptococcus neoformans showing that the identity varied between 36.5 and 93.9% among them (Table 1). The comprehensive comparative analysis of three-dimensional structures uncovered the basic understanding how CYP51 enzymes might maintain their conservation in human and fungi. As shown in Figure 2, the majority of amino-acids residues conserved in the folding of chains might play an essential structural role for their enzymatic function. The residues forming the surface of CYP51 proteins active site were highly conserved, such as Y118, F126, G127, V130 and T311 from the CYP51 proteins helix B’, B” helical turn and Helix I signature regions, respectively.

10The conserved amino acid sequences can be classified into three motifs and six putative substrate recognition sites (SRS). Among the three motifs, the most conserved FXXGXXXCXG is a heme binding domain containing a heme axial Cys ligand; and the E–R–R triad, formed by the motifs EXXR and PER, contributes to locking the heme pocket into position and to guarantee stabilization of the core structure (Figure 3). And among the six putative SRSs, the most thoroughly studied SRS1 and SRS4 can be used as landmarks of the fungal CYP51 (Figure 4).

11To crystallize C. albicans CYP51 proteins complexes with posaconazole and a tetrazole-based drug candidate VT-1161, Hargrove et al. used E. coli cells to express and purify the truncated C. albicans CYP51 proteins (56 kDa) without the 48-amino-acid-long N-terminal membrane anchor sequence. The structural analysis of C. albicans CYP51 proteins complexes carried out by Hargrove et al. showed that posaconazole had contacts with a set of 28 residues of C. albicans CYP51 proteins, while VT-1161 interacts with 22 amino acid residues, and forms the H-bond between its trifluoroethoxyphenyl oxygen and the imidazole ring of His377 of C. albicans CYP51 proteins [Table 2 from with slight modification]. Further, the X-ray structure of A. fumigates CYP51B complex with the tetrazole-based inhibitor VT-1598 (5FRB) determined also by showed the formation of an optimized hydrogen bond between the phenoxymethyl oxygen of VT-1598 and the imidazole ring nitrogen of His374 of A. fumigates CYP51B. Comparative structural analysis of the CYP51 proteins residue (His377 of C. albicans CYP51 proteins, His374 of A. fumigates CYP51B) among different organisms suggested it was highly conserved across fungal pathogens but not in human, supporting its fungus specificity and the role of H bonding in fungal CYP51/inhibitor complexes (Figure 2, 5).

12After the first structure of CYP51 proteins with the N-terminal region from S. cerevisiae (5EQB) in complex with itraconazole was elucidated and deposited in PDB, Keniya et al. concluded that the conformations of the three full-length fungal Cyp51 structures binding to itraconazole were close to that of the N-truncated C. albicans Cyp51 with posaconazole. In comparison these had only slight variations in residues conformations, such as C. glabrata Cyp51 I71, T75, I240; C. albicans Cyp51 A62, Q66, I231 and S. cerevisiae Cyp51 V70, M74, I239, all of which were within the ligand binding pocket and may not be significant due to modest electron densities in this region. Besides, the structures showed S. cerevisiae Cyp51-fluconazole or itraconazole had the binding sites in near identical conformations. The X-ray crystal structures determined by gives us insights into the CYP51 proteins reaction mechanism and emphasizes the identity of ligand-binding sites of fungal CYP51 families, providing a practical basis for the discovery and optimization of novel antifungals targeting at CYP51 families.

13In recent years, with the widespread use of CYP51-targeting drugs, drug-resistant Candida, Cryptococcus, and Aspergillus have emerged continuously. As shown in Table 3, in many resistant isolates, the decrease of susceptibility originated from mechanisms associated with CYP51, while other isolates not. Besides, transcription factors Pdr1 and Stb5, or the insertion of the Aft1 transposon into the CYP51 promoter region, can also cause a decrease in the sensitivity of the drugs. Transcription factors of non-pathogenic species may also bring some information, such as Set4 in S. cerevisiae, which represses CYP51 expression and reduces drug resistance. It is worth noting that drug resistance is often a combination of multiple mechanisms.

14The mechanisms associated with CYP51 are discussed below in detail.

15Candida spp., represented by C. albicans, is the most prominent pathogenic fungus. The spectrum of disease of invasive candidiasis ranges from minimally symptomatic candidaemia to fulminant sepsis with an associated mortality exceeding 70%. The resistance mechanisms of Candida spp. related with CYP51 includes point mutation, genomic plasticity, and upregulation of CYP51 meditated by the transportation factor Upc2.

16Point mutation (amino acid non-synonymous substitutions) of CYP51 proteins is a critical origination of reduced drug susceptibility. Three ways were proposed to explain the resistance mechanism: (1) the corresponding amino acids docked with azoles are changed, (2) the structure of the binding cavity is rearranged, leading to changed position of the azole molecule or the heme iron, disturbing the interaction between them, and (3) the access of the drug into the active site is blocked.

17In C. albicans, mutations of CYP51 proteins amino acid sequences frequently occurs on 105–165, 266–287, and 405–488. Among these mutations, N-terminal and C-terminal are more frequent than central regions, probably due to these terminal substitutions lead to changes in secondary and tertiary structure, especially substrate binding cavities, which are located in α-helix B, B′, C, and in their connection loops. And sequential replacement of ERG11 mutant alleles with wild-type alleles contributes to the reduction of resistance. The resistant C. albicans double point mutation Y132F G464S (Y140F G464S by S. cerevisiae numbering) were artificially introduced into S. cerevisiae CYP51, leading to a decrease in sensitivity of the latter. In addition, mutations located at different sites of CYP51 proteins provide different degrees of resistance enhancement. As an instance, K143R is stronger than F449V.

18The non-albicans Candida (NCAC) species also contains amino acid non-synonymous substitutions, such as Y132F in C. parapsilosis, Y132F and K143R in C. tropicalis.

19The newly emerged C. auris is a multi-drug resistant Candida that causes serious invasive infections, with a mortality rate approximate to 60%. CYP51 point mutation plays an important role in pan-azole resistance of C. auris. Nine typical amino acid substitutions have been identified, three of which are closely associated with geographic clades: F126T in South Africa, Y132F in Venezuela, and Y132F or K143R in India and Pakistan.

20Genomic plasticity, including aneuploidy and loss of heterozygosity (LOH), refers to the abnormal fungal chromosomal behavior induced by heat, oxidative stress or antifungal drugs. It is an important mechanism for fungal adaptation to the environment.

21Aneuploidy is a reversible fungal chromosomal adaptive behavior in response to drug stress. If the “selectivity” of the drug disappears, the cells will return to the euploid state. Aneuploidy after azole stress was first discovered in C. glabrata and was detailed studied in C. albicans.

22The aneuploidy of C. albicans chr1, chr3, chr5, chr6 and chrR has been reported under the stress of azoles treatments. Research on fluconazole-resistant strains has revealed that at least half of them carry aneuploid chromosomes. The duplication of the chr5’s left arm in C. albicans [named i(5L)] results in multiple copies and overexpression of CYP51 gene, contributing to azole resistance. Besides, aneuploidy of chr5 (carrying TAC1), chr3 (MRR1 and CDR1), Chr4 or chr6 (MDR1) also reduce drug susceptibility. Some aneuploid C. albicans chromosomes source from the mitotic defect in the process of quasi-fertility. There also exists an additional mechanism that, two diploid cells and one tetraploid cell are connected to each other to form a “trimeric,” then the tetraploid cell undergoes defective mitosis and results in two aneuploid progeny cells.

23An “Evolution Trap” (ET) strategy was proposed to suppress the occurrence of aneuploidy. The aneuploidy of a whole microflora can develop into multiple random directions, but once a specific inducing factor (stress X) is used to strictly limit its development direction, another treatment (treatment Y) can be applied to eliminate this trend and inhibits the generation of resistance. Such strategy has successfully pulled the minimum inhibitory concentration (MIC) against C. albicans carrying aneuploidy-sourced resistance back to normal level.

24Loss of heterozygosity is another branch of genomic plasticity leading to Candida species resistance. It is an irreversible process in diploid fungi, thus resulting the acquired resistance gene mutation (∗) become multiple (e.g., ERG11/ERG11∗→ ERG11∗/ ERG11∗), thus results in overexpression of such gene. LOH contains three mechanisms, (1) local recombination of chromosomes, (2) mitotic recombination between centromeres and related locus, (3) whole-chromosome loss and the remaining chromosome’s duplication.

25Transcription factors of CYP51 are tightly related to drug resistance. The Zn2-Cys6 transcription factor Upc2, located in Candida spp., is highly relevant to the increase of azole sensitivity. It has been confirmed that when Upc2 in C. albicans or C. parapsilosis or Upc2A in C. glabrata is deleted, the susceptibility to azoles will be enhanced. The C-terminal domain (CTD) of Upc2 is a novel α-helical fold with a deep hydrophobic pocket. Treatment with azole reduces the membrane ergosterol level, then ergosterol molecules that are previously bound to CTD dissociates from Upc2p. Thereby Upc2p relocates from the cytoplasm to the nucleus to activate CYP51 expression. It is worth noting that Upc2 only up-regulates the expression of CYP51 under azole stress conditions.

26The gain-of-function (GOF) mutation of Upc2 also contributes to Candida species increased drug resistance. Typical GOF point mutations inducing overexpression of CYP51 in C. albicans include A643V, G648D, G648S, and Y642F. Point mutations in UPC2 can reduce the sensitivity to azoles in combination with amino acid substitution of CYP51. For example, when combined with the CYP51G464S mutation, the MIC value of C. albicans carrying Upc2G648D against fluconazole is increased from 4 μg/ml to 16 μg/ml.

27Gain-of-function mutations were also found in C. tropicalis Upc2. Nucleotide substitutions T118G and G155A in CtUpc2 promoter increase the expression of this gene, and amino acid substitution G392E in CtUpc2p enhances drug resistance when expressed heterologously in S. cerevisiae.

28The GOF amino acid substitutions are often localized near the C terminus of Upc2p, where the activation domain of zinc-cluster transcription factors is found. Mutations in this region leading to reduced drug susceptibility include two possible mechanisms: (1) relieve Upc2 from a repressor that would otherwise keep this transcription factor inactive, (2) interfere with the transmembrane region of this protein, leading to Upc2p nuclear localization and initiation of CYP51 transcription.

29Cryptococcal meningitis (CM) is the most common infection caused by Cryptococcus spp., and is frequently recommended to be treated with fluconazole monotherapy in national guidelines. However, even with such treatment, the mortality of CM can exceed 50%, much of which owing to drug-induced cryptococcal resistance. Amino acid point mutation, genomic aneuploidy and Sre1-induced overexpression of CYP51 account for the reduced azole susceptibility.

30The amino acid point mutation G344S was found in CYP51 proteins of Cryptococcus neoformans var. grubii, resulting in multi-azole resistance. Besides, the substitution G484S may confer a change in the orientation of the P450 heme-binding domain, decreasing catalytic activity and azole binding of Cryptococcus neoformans CYP51 proteins (CnCYP51 proteins). And the substitution Y145F affords resistance to voriconazole but attenuates resistance to itraconazole and posaconazole. In Cryptococcus gattii CYP51 proteins, amino acid non-synonymous substitution N249D are deduced to result in azole resistance.

31As for genomic aneuploidy, Cryptococcus neoformans Chr1 disomy, which is common in heteroresistant isolates, results in duplication of CnCYP51 and reduced azole sensitivity. A recent report reveals that clinical fluconazole treatment can induce aneuploidy of C. neoformans in CM patients, and relapse of CM is associated with Chr1 disomy.

32Cryptococcus neoformans is haploid and aneuploid cells of this species mainly derive from the uncoupling of cell growth and nuclear division. Unlike C. albicans, the aneuploidy of Chr1 in C. neoformans only repeats the entire chromosome without forming segmental isochromosomes. A study indicates the detailed mechanism causing aneuploidy: final degradation of the septum is affected by fluconazole during cytokinesis, resulting in Chr1 disomy multinucleated cells, and these cells exhibit an increased potential to proliferate in the presence of fluconazole. However, another study points out that the fluconazole-induced multinucleated cells fail to propagate to form colonies in the presence of fluconazole, and chromosome missegregation of C. neoformans dividing cells has not been detected, suggesting C. neoformans forms aneuploid clones directly from uninucleated cells under fluconazole stress.

33Aneuploidy can be regulated by certain factors in Cryptococcal spp. For example, the decreased expression of AIF1 (apoptosis-inducing factor) conduces to maintain Chr1 aneuploidy, thereby contributes to a stable repeat of CYP51 and preserves resistance to azoles.

34Sterol regulatory element-binding protein (SREBPs) regulate the CYP51s’ expression in many species of fungal, including C. neoformans. Under azoles or hypoxic stress, SREBPs regulate the transcription of CYP51 by binding to the sterol regulatory element (SRE) in the promoter

35The SREBP in C. neoformans is Sre1. Sre1 is cleaved by Scp1and functions to regulate the expression of CYP51, thus plays a key role in drug resistance. Studies have shown that deletion of Sre1 converts the effect of azoles from fungistatic to fungicidal.

36The ability Aspergillus spp. to adapt to mammal hosts or external environment is a vital fungal characteristic that leads to treatment failure and the emergence of resistant isolates worldwide. Non-synonymous substitution of amino acids, transcription factors SrbA and AtrR, tandem repeats, and Dap proteins constitute the CYP51-related resistance mechanisms of Aspergillus spp.

37The lanosterol 14α-demethylase point amino acid mutations of A. fumigatus mainly appear in CYP51A, and G54, L98, G138, M220 and G448 are the hotspots. G54R/E/V and G138 lead to cross-resistance to itraconazole and posaconazole, and G448S results in voriconazole tolerance, while M220I/V/T/K can develop resistance to itraconazole, voriconazole, refconazole, and posaconazole. When the G138S point-substituted CYP51A in the resistant A. fumigatus was mutated back, the tolerance of the isolate diminished. Moreover, one mutation may have varied effects on resistance for different azoles. For example, in the heterologous expression experiment, G54W significantly reduces the susceptibility to itraconazole and posaconazole, while has almost no effect on voriconazole.

38Amino acids substitution also occurs in non-fumigatus Aspergillus species. Four mutations of A. flavus CYP51C (S196F, A324P, N423D and V465M) are correlated with voriconazole resistance. For A. clavatus CYP51A, E483K and P486S mutations may narrow the azole transport and therefore confer lower susceptibility. As for A. terreus and related species, M217T and M217V mutations of CYP51Ap was found correlating with posaconazole resistance.

39Notably, appliance of azole pesticides in agriculture is one of the reasons for the non-synonymous substitution of A. fumigatus CYP51 proteins. Mutations in this type include L98H, Y121F and T289A, which are often accompanied with tandem repeats of the CYP51 promoter.

40Tandem repeats include 34-base pair (TR34) and 46-base pair (TR46). CBC (CGAAT binding complex) binds to CGAAT of -293 to -289 position in the CYP51 promoter and downregulates CYP51A expression. Tandem repeats reduce the affinity of CBC and the promoter, upregulating CYP51A. Mechanism researches indicate that the presence of eight different nucleotides at the 3′end of TR34 lead to lower CBC affinity.

41The combination of CYP51 promoter tandem repeat and CYP51 proteins point mutation contains TR34/L98H/S297T/F495I and TR46/Y121F/T289A, leading to broad-spectrum azole resistance.. Studies on TR34/L98H have shown that L98H can cause a flexible change in the BC loop and IH loop of A. fumigatus CYP51A (AfCYP51A), which changes the position of the tyrosine107 and tyrosine 121 side chains. This modifies the ligand access channels in the AfCYP51A and prevents the binding of azoles toward the active heme. Moreover, TR34/L98H doesn’t incur a fitness cost or survival disadvantage to A. fumigatus. On the other hand, studies on TR46/Y121F/T289A indicate that the Y121F substitution seems to disrupt the H-bond between tyrosine and the heme center of AfCYP51A, resulting in the instability of enzyme’s active center.

42Besides, the insertion of Atf1 in the A. fumigatus CYP51A promoter may also be one of the factors leading to azole resistance. But it requires more researches to confirm whether the effect is direct.

43The transportation factor SrbA, as one of A. fumigatus SREBPs, modulates the expression of AfCYP51A. Different from C. neoformans, Scap homologue is absent in A. fumigatus, and SrbA directly binds to the 34 mer of AfCYP51A promoter without cleavage, regulating the synthesis of ergosterol. SrbA is directly activated by azole stress and is associated with the intrinsic resistance of A. fumigatus to fluconazole. An azole-resistant strain with TR46/Y121F/T289A can be sensitized to azoles by deletion of srbA. The intrinsic expression of CYP51 in such strain restores the MIC value to its original level.

44AtrR is a newly discovered fungal-specific Zn2-Cys6 transcription factor in Aspergillus spp. It modulates the expression of CYP51A by directly binding to the promoter of this gene. Deletion of AtrR results in hypersensitivity to azoles and invalidates the CYP51AG54E mutation that would otherwise render azole resistance.

45Damage Resistance Protein A (DapA), which belongs to the cytochrome b5-like heme-binding damage resistance protein (Dap) family, responds to azole treatment in a concentration-dependent manner in A. fumigatus. It co-localizes with CYP51A/B protein in the endoplasmic reticulum (ER), and then binds to the heme group to stabilize these CYP51 proteins. DapA is highly associated with the intrinsic azole resistance of A. fumigatus, and the deletion of DapA leads to hypersensitivity to azoles. Studies show that DapA may indirectly sense the azole stress at the downstream of SrbA.

46The study of azole antifungal antifungal agents can be traced back to 1944. Since then, imidazole (clotrimazole, miconazole, econazole, and ketoconazole) and two generations of triazoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole) successively entered into the clinic (partly shown in Table 4). Besides, there are several other CYP51 inhibitors used in the treatment of topical or superficial fungal infections, such as oxiconazole, sertaconazole, luliconazole, efinaconazole, and ravaconazole.

47Both imidazoles and triazoles exits adverse reactions caused by inhibition of human CYP450 (such as CYP3A4 and CYP2C9), due to the strong affinity to heme iron. Fortunately, replacement by 1-tetrazole could attenuate such affinity. Based on this idea, new compounds VT-1611, VT-1129, and VT-1598 have been developed (Figure 6).

48VT-1598 has a good affinity for the fungal CYP51 proteins, as the Kd of this compound to A. fumigatus CYP51B is 13 nM. Its antifungal spectrum is relatively broad. The MIC50 for azole-resistant C. albicans and C. glabrata is 0.124 and 1.19 μg/ml. Especially, the inhibition of VT-1598 against the clinical Coccidioides isolates is significantly better than that of fluconazole. The non-selective inhibition of VT-1598 to human CYP450 is weak, as IC50 for human CYP2C9 and CYP3A4 are both more than 200 μM, and the IC50 for CYP2C19 is 138 μM. When the oral dose (15 mg/kg/day) of VT-1598 is applied to mice, the Cmax is about 13 mg/L, the C24 h level is 6.7 mg/L and the half-life period is 22 h in plasma.

49VT-1598 has a high binding rate of plasma protein. When co-incubated with plasma at concentration of 1 mg or 5 mg/L in vitro, only less than 1% showed a free state. In vivo, when treated with 20 mg/kg of VT-1598 per day, the minimum plasma concentration (Cmin) was 32-fold greater than that of the 25 mg/kg dose of fluconazole.

50In the mouse model, VT-1598 has been used alone or in combination with amphotericin liposomes, and has achieved good efficiency for cryptococcal meningitis caused by C. neoformans or C. gatti infection. VT-1598 has also achieved significant preventive effects against mucosal candidiasis induced by sensitive or resistant Candida spp.. In addition, VT-1598 can be used to treat central nervous system coccidioidomycosis infected by C. posadasii and C. immitis. In May 2016, FDA granted orphan drug designation to VT-1598 for the treatment of Valley fever, a disease caused by Coccidioides infection.

51VT-1161 can tightly bind to the fungal CYP51 proteins and effectively inhibit the activity of such proteins. For example, the Kd of VT-1161 to C. albicans CYP51 proteins is less than 39 nM and IC50 ranges from 1.4 to 1.6 μM, resulting in the proportion of ergosterol to total sterols drop to only 3%. The MIC50 of VT-1161 against fluconazole-resistant C. albicans is 0.03 μg/ml. For T. rubrum CYP51 proteins, The Kd and IC50 values are 242 nM and 0.14 μM, respectively. Its non-selective inhibition of human CYP450 is also weak, appears in its IC50 of CYP2C9, CYP2C19 and CYP3A4 are 99, 72, and 65 μM. Pharmacokinetic experiments in mice showed that VT1161 has a wide distribution volume (1.4 L/kg), high oral bioavailability (73%), and long half-life period (>48 h). Phase II clinical trials showed oral VT-1161 plasma exposure for the 150 mg/24 weeks’ or 300 mg/24 weeks’ treatment groups were 3.81 and 8.33 μg/mL.

52Animal model studies have shown that VT1161 can be used to prevent or treat mucormycosis caused by Rhizopus arrhizus, and can also be used for treatment of mouse modeling infection or canine naturally occurring coccidioidomycosis. In addition, in a mouse model, VT1611 can treat oropharynx or vaginal Candidiasis caused by fluconazole sensitive or resistant C. albicans. Phase II clinical trials indicate that oral VT1161 has a good effect on treating human vulvar candidiasis, with a satisfactory tolerance and a low incidence of adverse reactions. Currently, oral VT-1161 has completed Phase II clinical trials for moderate – severe interdigital tinea pedis, vaginal candidiasis, and onychomycosis of the toenail. And phase III clinical trial is underway for Vaginal Candidiasis.

53VT-1129 has a similar skeleton to VT-1161, and shows a remarkable inhibitory activity against Cryptococcus CYP51 protein. For example, the Kd for C. neoformans, C. gattii, and C. grubii CYP51 proteins are about 11, 24, and 25 nM, respectively, and the corresponding IC50 are 0.16, 0.15, and 0.18 μM. VT-1129 can reduce the proportion of ergosterol to total sterols in C. neoformans to 11.5%, and only 0.12 μg/ml can totally inhibit the growth of C. neoformans. Its non-specific inhibition to human CYP450 is lower than that of the previous azole antifungals, appears in the IC50 to CYP2C9 and CYP2C19 are 87 and 110 μM, respectively, and for CYP3A4 is also higher than 79 μM. VT-1129 also inhibits the growth of azole or echinocandin resistant C. glabrata and C. krusei.

54The pharmacokinetic experiments in mice model showed that VT-1129’s half-life period is long (>6 days). The plasma and brain concentrations were still above the MIC values even after 20 and 32 days stopping oral treatment of VT-1129. The non-linear pharmacokinetic model has been approved to describe the correlation between concentrations of VT-1129 in plasma and in brain.

55At present, the research on VT-1129 in animal models is mainly focused on cryptococcal meningitis. VT-1129 significantly reduces fungal burden and improve survival rates during treatments. When treated with a dose of ≥ 3 mg/kg/day, the fungal burden was undetectable in most mice even 20 days after dosing was stopped. And treating at a dose of 20 mg/kg once daily reached a maximal survival benefit (100%). Because VT-1129 plasma and brain concentrations are related with fungal burden reductions, the loading dose-maintenance dose (LD-MD) strategy to treat cryptococcal meningitis seems feasible.

56CYP51 plays a crucial role in fungal invasive growth, hyphae formation and virulence, and inhibitors targeting CYP51 have always been an important component of antifungal agents. Further researches on fungal CYP51s might set about from the following aspects: First, while the detailed crystal structures of several susceptible pathogenic fungi CYP51 have been elaborated, those of drug-resistant variants are still in hypothesis. If those structures were elucidated, targeting at common drug-resistant CYP51 protein variants could probably be promising. Second, it deserves more in-depth researches to find out why some kind of amino acid point mutations (such as G54W in A. fumigatus CYP51A) could have varied effects on resistance for different azoles. Such researches may provide important ideas to minimize drug resistance. Third, the study of model organisms may also bring some inspiration. Such as Set4, which targets to ergosterol gene promoters with a Hap1-dependent manner under hypoxic conditions in S. cerevisiae, could downregulates the expression of CYP51. Whether homologous proteins and similar mechanisms exist in pathogenic fungi requires further researches. As long as they exist, new remedies may be put forward to activate Set4 to inhibit azole-induced CYP51 overexpression. Forth, it might be achievable to target other proteins as well as CYP51 simultaneously to maximize the therapeutic effect. There already exists some preliminary works focusing on this, and it is probably requisite to find out more accompanying targets. Fifth, the ”Evolution Trap”(ET) strategy, which successfully restored the sensitivity of C. albicans in vitro, might be practiced in vivo to investigate whether similar effects exist in animal models and further in humans. Aside from these, it is also hopeful for pharmaceutics amelioration to improve treatment efficacy. Novel drug delivery systems, such as liposomes, may confer better oral bioavailability on azoles.

57JZ contributed to the section of CYP51’s functions, inhibitors and drug resistance. LL contributed the structural analysis part of CYP51. QL, LY, YW, and YJ provided the revisions for this article.

58The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.